SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE),
Jim Hitchin, SpectraScience’s CEO, commented, “The addition of esophageal screening to our portfolio is an important milestone for our Company and one that we think can create significant additional value for our customers. Our WavSTAT® Optical Biopsy platform can be leveraged with additional software applications, and the addition of an esophageal screening function, will allow for a greater return on hardware investment and, more importantly, can extend the level of care that physicians provide to their patients. To accelerate this process, we have engaged Bielderman to manage the data collection from European hospitals that currently have our WavSTAT Optical Biopsy System.”
Generally speaking, quality clinical studies are less expensive in Europe. Through its selection of Bielderman, SpectraScience is employing its strategy of obtaining international approval first and marketing its product in Europe while concurrently moving forward with an FDA submission for approval in the United States.
SpectraScience holds approximately 60 patents worldwide that have been issued or are pending for its WavSTAT Optical Biopsy and LUMA® Cervical Imaging Systems. These non-invasive optical biopsy devices are used to diagnose tissue quickly to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. As noted above, evaluation of the WavSTAT for detection of pre-cancers in the throat (“Barrett’s esophagus”) is in process.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically illuminate tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
SOURCE SpectraScience, Inc.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All